VERA - Vera Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
VERA price evolution
VERA
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $364.13 | $394.75 | $416.37 | $172.02 |
| Long term investments | ||||
| Property, plant & equipment | $4.29 | $2.08 | $2.51 | $2.95 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $368.56 | $397.29 | $419.36 | $175.55 |
| Current liabilities | ||||
| Accounts payable | $4.6 | $4.66 | $5.21 | $11.12 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $26.46 | $18.42 | $14.54 | $22.3 |
| Long term debt | $50.47 | $50.26 | $50.07 | $49.88 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $79.5 | $69.42 | $65.81 | $73.86 |
| Shareholders' equity | ||||
| Retained earnings | -$417.82 | -$371.19 | -$337.49 | -$309.1 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $53.7 | |||
| Short term investments | ||||
| Net receivables | $0.05 | |||
| Inventory | ||||
| Total current assets | $172.02 | $125.7 | $82.54 | $54.26 |
| Long term investments | ||||
| Property, plant & equipment | $2.95 | $5.22 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.29 | |||
| Total investments | ||||
| Total assets | $175.55 | $131.44 | $83.75 | $54.55 |
| Current liabilities | ||||
| Accounts payable | $11.12 | $11.99 | $1.39 | $0.91 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $22.3 | $25.6 | $7.69 | $2.41 |
| Long term debt | $49.88 | $24.81 | $4.92 | |
| Total noncurrent liabilities | $1.92 | |||
| Total debt | ||||
| Total liabilities | $73.86 | $54.53 | $14.16 | $4.33 |
| Shareholders' equity | ||||
| Retained earnings | -$309.1 | -$213.11 | -$124.06 | -$91.45 |
| Other shareholder equity | $139.58 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $49.8 | $37.34 | $31.11 | $27.03 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | |||
| Interest expense | $2.83 | $3.19 | $2.28 | $0.9 |
| Net income | ||||
| Net income | -$46.63 | -$33.71 | -$28.38 | -$25.66 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $102.01 | $90.9 | $52.24 | |
| Operating income | -$52.24 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0 | -$0 | ||
| Interest expense | $4.19 | $0.76 | $0.17 | |
| Net income | ||||
| Net income | -$95.99 | -$89.06 | -$53.41 | |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$203.65 | -$241.96 | -$219.29 | -$39.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $280.72 | $279.98 | $276.54 | $133.54 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$18.42 | -$20.6 | $23.42 | $1.93 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | -$53.41 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$34.81 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$39.43 | -$70.55 | -$4.2 | -$0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $133.54 | $101.93 | $53.88 | $85.29 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.93 | -$36.22 | $25.97 | $50.44 |
News
Fundamentals
| Market cap | $1.61B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 55.03M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$134.38M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -11.97 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.44 |
|---|---|
| ROA | -39.50% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 13.76 |
| Quick ratio | N/A |